TCTR20201111002招募中3 期
Compared add-on Tiotropium handihaler and increasing dose of ICS in moderate and severe adult asthma who controlled with ICS/LABA
Ratchadapiseksompotch Research Fund0 个研究点目标入组 20 人开始时间: 2020年11月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •1.Diagnosis of asthma from clinical presentation and/or confirmed at screening with a bronchodilator reversibility (15â€30 minutes after 400 μg salbutamol) resulting in FEV1 or FVC increase of ≥ 12% and ≥ 200 mL or diurnal PEF variability > 10%
- •2.Diagnosis of asthma lasting 4 weeks or more
- •3.Patients were required to have been receiving maintenance treatment with stable medium-dose (eg 400 - 800 μg budesonide or equipotent dose) and high-dose ICS (eg > 800 μg budesonide or equipotent dose) and combination with a LABA, for at least 4 weeks prior to screening.
- •4.Symptomatic asthma was defined as ACT score of 5.Never smoked or be ex-smokers who stopped smoking at least 1 year prior to enrolment, with a smoking history of less than 10 pack-years
- •6.Reliever usage is only salbutamol.
排除标准
- •1.Diagnosis COPD by clinical and spirometry
- •2.Significant unstable concomitant disease e.g. IHD,CKD stage 5,Advanced stage cancer,Bed ridden,Immunocomprommise host[HIV or patients on immunosupressant]
- •3.On B-blocker or Biologic therapy within 6 momths prior to randomisation.
- •4.History of acute exacerbation or respiratory tract infection with in 4 weeks prior to randomisation.
- •5.Reliever usage is combination salbutamol and ipratropium bromide
- •6.Pregnancy
- •7.Patients were not permitted to take any investigational drug
- •or patients denied to enroll in the study.
研究者
相似试验
进行中（未招募）
不适用
Comparison of the Effects of Teriparatide with those of Risendronate on Lumbar Spine Volumetric Bone Mineral Density in GLucocorticpid-Induced Osteoporosis in Men - GHDHEUCTR2006-006315-68-DEEli Lilly and Company Limited104
进行中（未招募）
不适用
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Volumetric Bone Mineral Density in Glucocorticoid-Induced Osteoporosis in Men - NDEUCTR2006-006315-68-ITEli Lilly and Company104
进行中（未招募）
1 期
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip FractureEUCTR2008-002693-35-GBEli Lilly and Company Ltd171
进行中（未招募）
1 期
Comparison of Teriparatide with Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip FracturePostmenopausal Women and Men with Low Bone Mass and a Recent Pertrochanteric FractureMedDRA version: 17.1Level: LLTClassification code 10031288Term: Osteoporosis with fractureSystem Organ Class: 100000004859EUCTR2008-002693-35-SEEli Lilly and Company Ltd285
进行中（未招募）
1 期
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture - GHDKPostmenopausal Women and Men with Low Bone Mass and a Recent Pertrochanteric FractureMedDRA version: 9.1Level: LLTClassification code 10031282Term: OsteoporosisEUCTR2008-002693-35-NOEli Lilly and Company Ltd171